Drugs / MBP-426
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00355888 | Jun 2006 → Nov 2008 | cancer | Mebiopharm Co., Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00964080 | May 2009 → Oct 2012 | esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Mebiopharm Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MBP-426 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00964080 ↗ |
| Known as | Liposomal Oxaliplatin Suspension for Injection | “Several clinical trials have been carried out to investigate the side effects and dose-limiting toxicity of liposomal oxaliplatin, such as the assessment on Safety Study of...” PMID 35048809 ↗ 2022 |
| Route | Intravenous | “Given by Intravenous Infusion” NCT00355888 ↗ |